In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galen: European Specialist in US Markets

Executive Summary

In buying rights to market Lilly's Sarafem, Galen figures it can compete with Pfizer and GSK by detailing where they don't--Ob/Gyns. And in growing its valuation, Galen aims to compete with other public European small pharmas by focusing on the US.

You may also be interested in...

Galen/Barr: Burying the Hatchet

After this summer's failed merger talks between the two companies, Galen's three-pronged deal with US-based generics play Barr Laboratories might be the next best thing for Galen investors. At little cost, the deal removes much of the risk associated with the Northern-Irish company's legal battles. And even though agreements between branded players and their generics competitors often raise eyebrows at antitrust authorities, this deal's structure and focus on the heavily genericized oral contraceptives market may get it past the regulators.

Galen's Generic Gamble

Galen's $359 million acquisition of Pfizer's women's health portfolio fits in well with the group's strategy to date. But the structure of the deal also highlights Galen's increasing exposure to generic competition.

European Expansion: The Partnering Question

Executives from three biotechnology companies--Biogen, Gilead and Pharmion-told attendees at Windhover's 2d annual Marketing Pharmaceutical Innovation conference how the stark partnering/go-it-alone choices biotechs used to face (launch on your own, with a multinational, or in a network of local drug firms) are becoming far more nuanced as the partnering infrastructure available to the newer generation of start-ups expands to meet the broader opportunities.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts